Pergi ke luar talian dengan aplikasi Player FM !
Immunotherapy in HNSCC Series: Ep 2 - Perspectives from Surgical Oncology
Manage episode 326588332 series 2812899
Welcome to the second episode of IMPACT Medicom’s podcast series on Immunotherapy in Head and Neck Squamous Cell Carcinomas (HNSCC). This episode includes a discussion of:
- The role of the surgical oncologist in managing patients with HNSCC
- How immunotherapy fits into to the surgical oncologist's practice
Our Guest:
Our guest is Dr. Antoine Eskander, a head and neck surgical oncologist at Sunnybrook Health Sciences Centre and Assistant professor in the department of otolaryngology at the University of Toronto. He is also an adjunct scientist at the Institute for Clinical Evaluative Sciences.
This podcast episode was sponsored by Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
67 episod
Manage episode 326588332 series 2812899
Welcome to the second episode of IMPACT Medicom’s podcast series on Immunotherapy in Head and Neck Squamous Cell Carcinomas (HNSCC). This episode includes a discussion of:
- The role of the surgical oncologist in managing patients with HNSCC
- How immunotherapy fits into to the surgical oncologist's practice
Our Guest:
Our guest is Dr. Antoine Eskander, a head and neck surgical oncologist at Sunnybrook Health Sciences Centre and Assistant professor in the department of otolaryngology at the University of Toronto. He is also an adjunct scientist at the Institute for Clinical Evaluative Sciences.
This podcast episode was sponsored by Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
67 episod
Усі епізоди
×Selamat datang ke Player FM
Player FM mengimbas laman-laman web bagi podcast berkualiti tinggi untuk anda nikmati sekarang. Ia merupakan aplikasi podcast terbaik dan berfungsi untuk Android, iPhone, dan web. Daftar untuk melaraskan langganan merentasi peranti.